Literature DB >> 12152999

Hypomagnesemia and hypocalcemia in mycosis fungoides: a retrospective case series.

Matt Morgan1, Denise Maloney, Madeleine Duvic.   

Abstract

The most common variant of cutaneous T-cell lymphomas (CTCLs) is mycosis fungoides (MF), a malignant proliferation of atypical CD4+ CD45Ro+ T-cells that initially proliferate in the skin and later invades lymph nodes and other organs including the blood (Sezary syndrome). The pathogenesis of CTCL is largely unknown. We present definitive data showing a correlation between degree and prevalence of hypomagnesemia and hypocalcemia and clinical stage of MF. Hypomagnesemia was present in 22.2% of MF patients with early stage (n = 27), 38.5% of intermediate stage (n = 13), and 67.5% of advanced stage disease (n = 40). Hypocalcemia was present in 8.3% of MF patients with early stage (n = 24), 54.5% with intermediate stage (n = 11), and 61.0% with advanced stage disease (n = 41). The odds ratios for having hypomagnesemia and hypocalcemia in patients with stage II or higher MF compared with stage I patients were 5.33 and 16.24, respectively. Hypomagnesemia has been associated with immune function abnormalities including the development of T-cell leukemia-lymphoma in rats. We hypothesize that the hypomagnesemia may play a role in the progression or pathogenesis of MF or the Sezary syndrome (SS). This retrospective case series is the first study ever to report a relationship between serum cations and CTCL in humans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12152999     DOI: 10.1080/10428190290026367

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

Review 1.  Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.

Authors:  Swaminathan P Iyer; Francine F Foss
Journal:  Oncologist       Date:  2015-06-22

2.  Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.

Authors:  Anne M Noonan; Robin A Eisch; David J Liewehr; Tristan M Sissung; David J Venzon; Thomas P Flagg; Mark C Haigney; Seth M Steinberg; William D Figg; Richard L Piekarz; Susan E Bates
Journal:  Clin Cancer Res       Date:  2013-04-15       Impact factor: 12.531

3.  Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

Authors:  Richard L Piekarz; Robin Frye; Maria Turner; John J Wright; Steven L Allen; Mark H Kirschbaum; Jasmine Zain; H Miles Prince; John P Leonard; Larisa J Geskin; Craig Reeder; David Joske; William D Figg; Erin R Gardner; Seth M Steinberg; Elaine S Jaffe; Maryalice Stetler-Stevenson; Stephen Lade; A Tito Fojo; Susan E Bates
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

4.  A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).

Authors:  Simon J Harrison; Mark Bishton; Susan E Bates; Steven Grant; Richard L Piekarz; Ricky W Johnstone; Yun Dai; Becki Lee; Maria E Araujo; H Miles Prince
Journal:  Epigenomics       Date:  2012-10       Impact factor: 4.778

5.  Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.

Authors:  Francine Foss; Steven Horwitz; Barbara Pro; H Miles Prince; Lubomir Sokol; Barbara Balser; Julie Wolfson; Bertrand Coiffier
Journal:  J Hematol Oncol       Date:  2016-03-10       Impact factor: 17.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.